Introducing a webinar on clinical insights and practical strategies for integrating In-line aerosol delivery with high-flow nasal cannula (HFNC) on Thursday 12 March 12:00-1:00 PM EST by Matthew Dartt, MBA, RRT, RRT-ACCS, Assistant Director of Respiratory Therapy, UCLA Health
Aerogen
Corporate Statement
Who we are
Aerogen is a global company headquartered in Galway, Ireland that designs, manufactures and commercialises market-leading products for the acute care sector. With over 25 years of experience, 300 international patents and associated with over 200 clinical papers and publications, Aerogen technology has been used to treat 16 million patients in 75 countries worldwide.1
Our purpose
To positively impact patient outcomes through superior aerosol drug delivery
Our promise
To keep creating industry leading products that deliver improved patient outcomes>
Aerogen
News
The 12th Zenith Award, a prestigious accolade in the respiratory care profession, signifies over a decade of unwavering commitment to excellence and innovation.
Empowering Healthcare Professionals with Cutting-Edge Education and Resources
Aerogen
Media Contacts
Media Contacts
Before publishing any piece on Aerogen we invite you to reach out to our Communications team who can provide further clarity where required. The mailbox marketing@aerogen.com is monitored consistently and is the most efficient way to reach the communications team. Please note, only media enquiries will be responded to. If you have other needs and are looking to contact another group at Aerogen, please visit the contact page
Aerogen
Follow Aerogen
- Data on file
